Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
Recruiting · NCT04708587 · Interventional (participants receive a specific treatment) · Lead sponsor: Yonsei University
View the official record on ClinicalTrials.gov →Interventions studied
dual anti-platelet therapy 3months or lessdual anti-platelet therapy at least 6 months
What this trial is about
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.
Who can take part
Age range
19 Years to 84 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Over 19 years old
- Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR \<45 / \<30 / \<15 or dialysis)
- Patients treated with a new generation drug eluting stent.
- Patients who signed consent form
Exclusion criteria
- Over 85 years old
- Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke, dementia or central nervous system damage within 1 year 3) Head trauma or brain surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6) Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8) In case of major surgery, trauma or bleeding within 3 weeks
- Patients who need oral anticoagulant
- Pregnant women or women of childbearing age
- Life expectancy is less than 1 year
- Patients with a history of intracranial bleeding
- Moderate to severe hepatic impairment (Child-Pugh class B or C)
Where it is running
1 location listed.
- Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine - Seoul, South Korea